Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Carina Lorenz"'
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/2ae2ae866e5540269e9625ab27bafd0c
Autor:
Johannes Brägelmann, Carina Lorenz, Sven Borchmann, Kazuya Nishii, Julia Wegner, Lydia Meder, Jenny Ostendorp, David F. Ast, Alena Heimsoeth, Takamasa Nakasuka, Atsuko Hirabae, Sachi Okawa, Marcel A. Dammert, Dennis Plenker, Sebastian Klein, Philipp Lohneis, Jianing Gu, Laura K. Godfrey, Jan Forster, Marija Trajkovic-Arsic, Thomas Zillinger, Mareike Haarmann, Alexander Quaas, Stefanie Lennartz, Marcel Schmiel, Joshua D’Rozario, Emily S. Thomas, Henry Li, Clemens A. Schmitt, Julie George, Roman K. Thomas, Silvia von Karstedt, Gunther Hartmann, Reinhard Büttner, Roland T. Ullrich, Jens T. Siveke, Kadoaki Ohashi, Martin Schlee, Martin L. Sos
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Kinase inhibitors are widely used to treat cancer, however patients frequently develop resistance. Here, the authors investigate adaption mechanisms during drug persistence and show that stimulation of the innate immunity sensor RIG-I enhances cancer
Externí odkaz:
https://doaj.org/article/9def69d01bbd4809814653393e15ac1f
Autor:
Marcel A. Dammert, Johannes Brägelmann, Rachelle R. Olsen, Stefanie Böhm, Niloufar Monhasery, Christopher P. Whitney, Milind D. Chalishazar, Hannah L. Tumbrink, Matthew R. Guthrie, Sebastian Klein, Abbie S. Ireland, Jeremy Ryan, Anna Schmitt, Annika Marx, Luka Ozretić, Roberta Castiglione, Carina Lorenz, Ron D. Jachimowicz, Elmar Wolf, Roman K. Thomas, John T. Poirier, Reinhard Büttner, Triparna Sen, Lauren A. Byers, H. Christian Reinhardt, Anthony Letai, Trudy G. Oliver, Martin L. Sos
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
The expression of oncogenic MYC paralogs in small cell lung cancer is mutually exclusive. In this study, the authors show that MYC, but not MYCN or MYCL, represses BCL2, resulting in cells that are uniquely sensitive to apoptosis, and find that CHK1
Externí odkaz:
https://doaj.org/article/05063d53c99b4d6497e917f9551d71f7
Autor:
Johannes Brägelmann, Marcel A. Dammert, Felix Dietlein, Johannes M. Heuckmann, Axel Choidas, Stefanie Böhm, André Richters, Debjit Basu, Verena Tischler, Carina Lorenz, Peter Habenberger, Zhizhou Fang, Sandra Ortiz-Cuaran, Frauke Leenders, Jan Eickhoff, Uwe Koch, Matthäus Getlik, Martin Termathe, Muhammad Sallouh, Zoltán Greff, Zoltán Varga, Hyatt Balke-Want, Christopher A. French, Martin Peifer, H. Christian Reinhardt, László Örfi, György Kéri, Sascha Ansén, Lukas C. Heukamp, Reinhard Büttner, Daniel Rauh, Bert M. Klebl, Roman K. Thomas, Martin L. Sos
Publikováno v:
Cell Reports, Vol 20, Iss 12, Pp 2833-2845 (2017)
Kinase inhibitors represent the backbone of targeted cancer therapy, yet only a limited number of oncogenic drivers are directly druggable. By interrogating the activity of 1,505 kinase inhibitors, we found that BRD4-NUT-rearranged NUT midline carcin
Externí odkaz:
https://doaj.org/article/65260813004b4d5e8d198b9f59d2baa6
Autor:
Roman K. Thomas, H. Christian Reinhardt, Martin L. Sos, Martin Peifer, Alison M. Schram, F. Thomas Wunderlich, Kevan M. Shokat, Thorsten Persigehl, Reinhard Büttner, Anna Schmitt, Sebastian Klein, Hannah L. Tumbrink, Johannes Brägelmann, Carina Lorenz, Marcel A. Dammert, Dennis Plenker, Lisa Werr
Supplementary Figure from CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::006bacef01864bbdf70bcd37747e88ea
https://doi.org/10.1158/1535-7163.22522992.v1
https://doi.org/10.1158/1535-7163.22522992.v1
Autor:
Roman K. Thomas, H. Christian Reinhardt, Martin L. Sos, Martin Peifer, Alison M. Schram, F. Thomas Wunderlich, Kevan M. Shokat, Thorsten Persigehl, Reinhard Büttner, Anna Schmitt, Sebastian Klein, Hannah L. Tumbrink, Johannes Brägelmann, Carina Lorenz, Marcel A. Dammert, Dennis Plenker, Lisa Werr
NRG1 fusions are recurrent somatic genome alterations occurring across several tumor types, including invasive mucinous lung adenocarcinomas and pancreatic ductal adenocarcinomas and are potentially actionable genetic alterations in these cancers. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eb5b84d85a40ab02fd23cb6c8c99405
https://doi.org/10.1158/1535-7163.c.6543543.v1
https://doi.org/10.1158/1535-7163.c.6543543.v1
Autor:
Johannes M. Heuckmann, Martin L. Sos, Lukas Heukamp, Jürgen Wolf, Frank Griesinger, Reinhard Büttner, Erik Thunnissen, Roopika Menon, Tobias Zacherle, Gunther Hartmann, Pepijn Schellen, Thomas Wurdinger, Alexander Kluge, Thorsten Persigehl, Carsten Kobe, Juliane Daßler-Plenker, Johannes Brägelmann, Judith Müller, Andreas H. Scheel, Carina Lorenz, Richard Riedel, Adrianus J. de Langen, Miriam Bertrand, Dennis Plenker
Purpose: We sought to investigate the clinical response to MET inhibition in patients diagnosed with structural MET alterations and to characterize their functional relevance in cellular models.Experimental Design: Patients were selected for treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fc2b8e2c6f4e840563f222c8458c3e6
https://doi.org/10.1158/1078-0432.c.6524654
https://doi.org/10.1158/1078-0432.c.6524654
Autor:
Jonas Lategahn, Hannah L. Tumbrink, Carsten Schultz-Fademrecht, Alena Heimsoeth, Lisa Werr, Janina Niggenaber, Marina Keul, Fatma Parmaksiz, Matthias Baumann, Sascha Menninger, Eldar Zent, Ina Landel, Jörn Weisner, Kirujan Jeyakumar, Leonie Heyden, Nicole Russ, Fabienne Müller, Carina Lorenz, Johannes Brägelmann, Inga Spille, Tobias Grabe, Matthias P. Müller, Johannes M. Heuckmann, Bert M. Klebl, Peter Nussbaumer, Martin L. Sos, Daniel Rauh
Publikováno v:
Journal of Medicinal Chemistry. 65:6643-6655
Despite the clinical efficacy of epidermal growth factor receptor (EGFR) inhibitors, a subset of patients with non-small cell lung cancer displays insertion mutations in exon20 in EGFR and Her2 with limited treatment options. Here, we present the dev
Publikováno v:
Annual Review of Cancer Biology. 5:79-94
Breast cancer comprises a heterogeneous group of tumor subtypes, whether defined by immunohistochemistry of key proteins, RNA expression profiles, or genetic alterations, and each of these subtypes may benefit from a distinct treatment approach. Howe
Autor:
Carina Lorenz, John T. Poirier, Lauren Averett Byers, Jeremy Ryan, Marcel A. Dammert, Annika Marx, Roman K. Thomas, Johannes Brägelmann, Matthew R. Guthrie, Hannah L. Tumbrink, Reinhard Büttner, Triparna Sen, Ron D. Jachimowicz, Christopher P. Whitney, Niloufar Monhasery, Anna Schmitt, Rachelle R. Olsen, Milind D. Chalishazar, Trudy G. Oliver, Elmar Wolf, Sebastian Klein, Roberta Castiglione, Stefanie Böhm, Anthony Letai, Luka Ozretić, Abbie S. Ireland, H. Christian Reinhardt, Martin L. Sos
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
Nat Commun
Nature Communications
Nat Commun
Nature Communications
MYC paralogs are frequently activated in small cell lung cancer (SCLC) but represent poor drug targets. Thus, a detailed mapping of MYC-paralog-specific vulnerabilities may help to develop effective therapies for SCLC patients. Using a unique cellula